{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T21:01:08Z","timestamp":1776805268412,"version":"3.51.2"},"reference-count":49,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurologic Clinics"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ncl.2025.11.006","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T20:39:54Z","timestamp":1768336794000},"page":"291-304","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pediatric Optic Neuritis"],"prefix":"10.1016","volume":"44","author":[{"given":"Osama Al","family":"Deyabat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Aman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tuan Anh","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mays","family":"El-Dairi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ncl.2025.11.006_bib1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s11910-020-1024-x","article-title":"Update on pediatric optic neuritis","volume":"20","author":"Gise","year":"2020","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"5","key":"10.1016\/j.ncl.2025.11.006_bib2","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/ICU.0000000000000509","article-title":"Pediatric optic neuritis","volume":"29","author":"Lehman","year":"2018","journal-title":"Curr Opin Ophthalmol"},{"issue":"9","key":"10.1016\/j.ncl.2025.11.006_bib3","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199202273260901","article-title":"A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis","volume":"326","author":"Beck","year":"1992","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ncl.2025.11.006_bib4","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1212\/01.wnl.0000224757.69746.fb","article-title":"The clinical features, MRI findings, and outcome of optic neuritis in children","volume":"67","author":"Wilejto","year":"2006","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.ncl.2025.11.006_bib5","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.ajo.2014.05.036","article-title":"Visual outcomes in pediatric optic neuritis","volume":"158","author":"Wan","year":"2014","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"10.1016\/j.ncl.2025.11.006_bib6","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1001\/jamaneurol.2017.4601","article-title":"Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"75","author":"Hacohen","year":"2018","journal-title":"JAMA Neurol"},{"issue":"3","key":"10.1016\/j.ncl.2025.11.006_bib7","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.ophtha.2019.09.032","article-title":"Population-based incidence of pediatric and adult optic neuritis and the risk of multiple sclerosis","volume":"127","author":"Lee","year":"2020","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.ncl.2025.11.006_bib8","doi-asserted-by":"crossref","first-page":"855","DOI":"10.3390\/children8100855","article-title":"Pediatric optic neuritis: description of four cases and review of the literature","volume":"8","author":"Presicci","year":"2021","journal-title":"Children"},{"issue":"8","key":"10.1016\/j.ncl.2025.11.006_bib9","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1038\/s41433-025-03683-8","article-title":"Prevalence of pediatric and adult optic neuritis in the United States from 2016 to 2023","volume":"39","author":"Abbass","year":"2025","journal-title":"Eye (Lond)"},{"issue":"8","key":"10.1016\/j.ncl.2025.11.006_bib10","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.ophtha.2022.03.021","article-title":"The pediatric optic neuritis prospective outcomes study: two-year results","volume":"129","author":"Pineles","year":"2022","journal-title":"Ophthalmology"},{"issue":"1\u20132","key":"10.1016\/j.ncl.2025.11.006_bib11","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jns.2011.02.018","article-title":"Neuromyelitis optica and astrocytic damage in its pathogenesis","volume":"306","author":"Fujihara","year":"2011","journal-title":"J Neurol Sci"},{"issue":"2","key":"10.1016\/j.ncl.2025.11.006_bib12","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S1091-8531(99)70078-9","article-title":"Optic neuritis in children: clinical features and visual outcome","volume":"3","author":"Brady","year":"1999","journal-title":"J Am Assoc Pediatr Ophthalmol Strabismus"},{"issue":"4","key":"10.1016\/j.ncl.2025.11.006_bib13","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1080\/08820530390895172","article-title":"Optic neuritis in adults and children","volume":"18","author":"Boomer","year":"2003","journal-title":"Semin Ophthalmol"},{"key":"10.1016\/j.ncl.2025.11.006_bib14","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1590\/S0004-282X2001000300001","article-title":"The clinical profile of childhood optic neuritis","volume":"59","author":"Lana-Peixoto","year":"2001","journal-title":"Arq Neuropsiquiatr"},{"issue":"5","key":"10.1016\/j.ncl.2025.11.006_bib15","first-page":"441","article-title":"Pediatric optic neuritis and risk of multiple sclerosis: meta-analysis of observational studies","volume":"15","author":"Waldman","year":"2011","journal-title":"J"},{"issue":"2","key":"10.1016\/j.ncl.2025.11.006_bib16","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2025.11.006_bib17","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.msard.2018.11.026","article-title":"Unique characteristics of optical coherence tomography (OCT) results and visual acuity testing in myelin oligodendrocyte glycoprotein (MOG) antibody positive pediatric patients","volume":"28","author":"Narayan","year":"2019","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"10.1016\/j.ncl.2025.11.006_bib18","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3109\/01658107.2014.984230","article-title":"Longitudinal changes in retinal nerve fibre layer thickness after an isolated unilateral retrobulbar optic neuritis: 1-year results","volume":"39","author":"Yau","year":"2015","journal-title":"Neuroophthalmology"},{"key":"10.1016\/j.ncl.2025.11.006_bib19","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3389\/fneur.2017.00493","article-title":"The contribution of optical coherence tomography in neuromyelitis optica spectrum disorders","volume":"8","author":"Mateo","year":"2017","journal-title":"Front Neurol"},{"issue":"3","key":"10.1016\/j.ncl.2025.11.006_bib20","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1023\/B:DOOP.0000005335.28820.05","article-title":"Optic neuritis in children--clinical and electrophysiological follow-up","volume":"107","author":"Tekavcic-Pompe","year":"2003","journal-title":"Doc Ophthalmol Adv Ophthalmol"},{"issue":"7","key":"10.1016\/j.ncl.2025.11.006_bib21","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1007\/s00415-023-11634-0","article-title":"Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) - revised recommendations of the neuromyelitis optica study group (NEMOS). part I: diagnosis and differential diagnosis","volume":"270","author":"Jarius","year":"2023","journal-title":"J Neurol"},{"issue":"1","key":"10.1016\/j.ncl.2025.11.006_bib22","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00415-023-11910-z","article-title":"Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the neuromyelitis optica study group (NEMOS). part II: attack therapy and long-term management","volume":"271","author":"K\u00fcmpfel","year":"2024","journal-title":"J Neurol"},{"issue":"3","key":"10.1016\/j.ncl.2025.11.006_bib23","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: international MOGAD panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol"},{"issue":"12","key":"10.1016\/j.ncl.2025.11.006_bib24","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.jocn.2008.05.002","article-title":"Post-vaccination encephalomyelitis: literature review and illustrative case","volume":"15","author":"Huynh","year":"2008","journal-title":"J Clin Neurosci"},{"issue":"10","key":"10.1016\/j.ncl.2025.11.006_bib25","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1177\/1352458513484547","article-title":"International pediatric multiple sclerosis study group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions","volume":"19","author":"Krupp","year":"2013","journal-title":"Mult Scler"},{"key":"10.1016\/j.ncl.2025.11.006_bib26","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ajo.2018.07.020","article-title":"Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis: clinical characteristics, radiologic clues, and outcome","volume":"195","author":"Chen","year":"2018","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"10.1016\/j.ncl.2025.11.006_bib27","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1474-4422(19)30488-0","article-title":"Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study","volume":"19","author":"Armangue","year":"2020","journal-title":"Lancet Neurol"},{"issue":"16 Suppl 2","key":"10.1016\/j.ncl.2025.11.006_bib28","first-page":"S7","article-title":"Consensus definitions proposed for pediatric multiple sclerosis and related disorders","volume":"68","author":"Krupp","year":"2007","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.ncl.2025.11.006_bib29","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000528","article-title":"Real-world validation of the 2017 McDonald criteria for pediatric MS","volume":"6","author":"Wong","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"10","key":"10.1016\/j.ncl.2025.11.006_bib30","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1212\/01.wnl.0000344163.65326.48","article-title":"Pediatric optic neuritis: brain MRI abnormalities and risk of multiple sclerosis","volume":"72","author":"Bonhomme","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2025.11.006_bib31","first-page":"59","article-title":"Infectious optic neuropathies: a clinical update","volume":"7","author":"Kahloun","year":"2015","journal-title":"Eye Brain"},{"issue":"8","key":"10.1016\/j.ncl.2025.11.006_bib32","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1001\/archopht.1988.01060140207023","article-title":"The optic neuritis treatment trial","volume":"106","author":"Beck","year":"1988","journal-title":"Arch Ophthalmol"},{"issue":"6","key":"10.1016\/j.ncl.2025.11.006_bib33","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1001\/jamaneurol.2018.0024","article-title":"Effect of treating acute optic neuritis with bioequivalent oral vs intravenous corticosteroids: a randomized clinical trial","volume":"75","author":"Morrow","year":"2018","journal-title":"JAMA Neurol"},{"issue":"4","key":"10.1016\/j.ncl.2025.11.006_bib34","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/jnnp-2017-316286","article-title":"Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders","volume":"89","author":"Bonnan","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"10.1016\/j.ncl.2025.11.006_bib35","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s11940-019-0541-x","article-title":"Treatment approaches for MOG-Ab-associated demyelination in children","volume":"21","author":"Hacohen","year":"2019","journal-title":"Curr Treat Options Neurol"},{"issue":"5","key":"10.1016\/j.ncl.2025.11.006_bib36","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000837","article-title":"Treatment and outcome of aquaporin-4 antibody\u2013positive NMOSD","volume":"7","author":"Paolilo","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"issue":"9","key":"10.1016\/j.ncl.2025.11.006_bib37","first-page":"e985","article-title":"Therapeutic response in pediatric neuromyelitis optica spectrum disorder","volume":"100","author":"Pizzolato","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2025.11.006_bib38","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40893-018-0035-9","article-title":"Use of rituximab and risk of re-hospitalization for children with neuromyelitis optica spectrum disorder","volume":"3","author":"Gmuca","year":"2018","journal-title":"Mult Scler Demyelinating Disord"},{"key":"10.1016\/j.ncl.2025.11.006_bib39","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ajo.2022.01.015","article-title":"Vision prognosis and associated factors of optic neuritis in dependence of glial autoimmune antibodies","volume":"239","author":"Yang","year":"2022","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ncl.2025.11.006_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0171880","article-title":"Impact of the anti-aquaporin-4 autoantibody on inner retinal structure, function and structure-function associations in Japanese patients with optic neuritis","volume":"12","author":"Matsumoto","year":"2017","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.ncl.2025.11.006_bib41","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1002\/ana.24409","article-title":"Oligoclonal bands predict multiple sclerosis in children with optic neuritis","volume":"77","author":"Heussinger","year":"2015","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.ncl.2025.11.006_bib42","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/bjophthalmol-2020-317524","article-title":"Clinical predictive factors for diagnosis of MOG-IgG and AQP4-IgG related paediatric optic neuritis: a Chinese cohort study","volume":"106","author":"Yang","year":"2022","journal-title":"Br J Ophthalmol"},{"issue":"22","key":"10.1016\/j.ncl.2025.11.006_bib43","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of satralizumab in neuromyelitis optica spectrum disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ncl.2025.11.006_bib44","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/S1474-4422(24)00077-2","article-title":"Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial","volume":"23","author":"Cree","year":"2024","journal-title":"Lancet Neurol"},{"issue":"6","key":"10.1016\/j.ncl.2025.11.006_bib45","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/ana.26626","article-title":"Ravulizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"93","author":"Pittock","year":"2023","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.ncl.2025.11.006_bib49","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200065","article-title":"Early immunotherapy and longer corticosteroid treatment are associated with lower risk of relapsing disease course in pediatric MOGAD","volume":"10","author":"Nosadini","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"issue":"2","key":"10.1016\/j.ncl.2025.11.006_bib51","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jamaneurol.2019.3283","article-title":"Using acute optic neuritis trials to assess neuroprotective and remyelinating therapies in multiple sclerosis","volume":"77","author":"Andorr\u00e0","year":"2020","journal-title":"JAMA Neurol"},{"issue":"3","key":"10.1016\/j.ncl.2025.11.006_bib52","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S1474-4422(16)00004-1","article-title":"Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial","volume":"15","author":"Raftopoulos","year":"2016","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.ncl.2025.11.006_bib53","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3390\/biomedicines10010192","article-title":"Neuroprotective effects of novel treatments on acute optic neuritis\u2014a meta-analysis","volume":"10","author":"Tsai","year":"2022","journal-title":"Biomedicines"}],"container-title":["Neurologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861925000908?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861925000908?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T20:20:43Z","timestamp":1776802843000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733861925000908"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0733861925000908"],"URL":"https:\/\/doi.org\/10.1016\/j.ncl.2025.11.006","relation":{},"ISSN":["0733-8619"],"issn-type":[{"value":"0733-8619","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pediatric Optic Neuritis","name":"articletitle","label":"Article Title"},{"value":"Neurologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ncl.2025.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}